Synthesis and Testing of a Focused Phenothiazine Library for Binding to HIV-1 TAR RNA

Chemistry and Biology

Volumn 13, Issue 9, 2006, Pages 993-1000

  Mayer, Moriz ^a   Lang, P Therese ^a   Gerber, Sabina ^a   Madrid, Peter B ^a   Pinto, Irene Gómez ^a   Guy, R Kiplin ^a   James, Thomas L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHENOTHIAZINE DERIVATIVE; VIRUS RNA;

ARTICLE; BINDING SITE; CHEMISTRY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

BINDING SITES; HIV LONG TERMINAL REPEAT; HIV-1; MAGNETIC RESONANCE SPECTROSCOPY; PHENOTHIAZINES; RNA, VIRAL; STRUCTURE-ACTIVITY RELATIONSHIP;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33748561836     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2006.07.009     Document Type: Article

References (23)

1. Rees D.C., Congreve M., Murray C.W., and Carr R. Fragment-based lead discovery. Nat. Rev. Drug Discov. 3 (2004) 660-672
2. Hajduk P.J., Gomtsyan A., Didomenico S., Cowart M., Bayburt E.K., Solomon L., Severin J., Smith R., Walter K., Holzman T.F., et al. Design of adenosine kinase inhibitors from the NMR-based screening of fragments. J. Med. Chem. 43 (2000) 4781-4786
3. Hermann T. Strategies for the design of drugs targeting RNA and RNA-protein complexes. Angew. Chem. Int. Ed. Engl. 39 (2000) 1891-1905
4. Aboul-ela F., Karn J., and Varani G. The structure of the human immunodeficiency virus type-1 TAR RNA reveals principles of RNA recognition by Tat protein. J. Mol. Biol. 253 (1995) 313-332
5. Cheng A.C., Calabro V., and Frankel A.D. Design of RNA-binding proteins and ligands. Curr. Opin. Struct. Biol. 11 (2001) 478-484
6. Hamy F., Felder E.R., Heizmann G., Lazdins J., Aboul-ela F., Varani G., Karn J., and Klimkait T. An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. Proc. Natl. Acad. Sci. USA 94 (1997) 3548-3553
7. Lind K.E., Du Z., Fujinaga K., Peterlin B.M., and James T.L. Structure-based computational database screening, in vitro assay, and NMR assessment of compounds that target TAR RNA. Chem. Biol. 9 (2002) 185-193
8. Renner S., Ludwig V., Boden O., Scheffer U., Gobel M., and Schneider G. New inhibitors of the Tat-TAR RNA interaction found with a "fuzzy" pharmacophore model. ChemBioChem 6 (2005) 1119-1125
9. Hwang S., Tamilarasu N., Kibler K., Cao H., Ali A., Ping Y.H., Jeang K.T., and Rana T.M. Discovery of a small molecule Tat-trans-activation-responsive RNA antagonist that potently inhibits human immunodeficiency virus-1 replication. J. Biol. Chem. 278 (2003) 39092-39103
10. Davis B., Afshar M., Varani G., Murchie A.I.H., Karn J., Lentzen G., Drysdale M.J., Bower J., Potter A.J., Starkey I.D., et al. Rational design of inhibitors of HIV-1 TAR RNA through the stabilisation of electrostatic "hot spots". J. Mol. Biol. 336 (2004) 343-356
11. Mayer M., and James T.L. NMR-based characterization of phenothiazines as a RNA binding scaffold. J. Am. Chem. Soc. 126 (2004) 4453-4460
12. Mayer M., and James T.L. Discovery of ligands by a combination of computational and NMR-based screening: RNA as an example target. Methods Enzymol. 394 (2005) 571-587
13. Yu L., Oost T.K., Schkeryantz J.M., Yang J., Janowick D., and Fesik S.W. Discovery of aminoglycoside mimetics by NMR-based screening of Escherichia coli A-site RNA. J. Am. Chem. Soc. 125 (2003) 4444-4450
14. Fejzo J., Lepre C.A., Peng J.W., Bemis G.W., Ajay, Murcko M.A., and Moore J.M. The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. Chem. Biol. 6 (1999) 755-769
15. Mayer M., and James T.L. Detecting ligand binding to a small RNA target via saturation transfer difference NMR experiments in D(2)O and H(2)O. J. Am. Chem. Soc. 124 (2002) 13376-13377
16. Du Z., Lind K.E., and James T.L. Structure of TAR RNA complexed with a Tat-TAR interaction nanomolar inhibitor that was identified by computational screening. Chem. Biol. 9 (2002) 707-712
17. Yale H.L., Sowinski F., and Bernstein J. 10-(3-dimethylaminopropyl)-2-(trifluoromethyl)-phenothiazine hydrochloride (VESPRIN) and related compounds 1. J. Am. Chem. Soc. 79 (1957) 4375-4379
18. Filip S.V., Silberg I.A., Surducan E., Vlassa M., and Surducan V. Microwave-assisted phenothiazine preparation by thionation of diphenylamines. Synth. Commun. 28 (1998) 337-345
19. Villemin D., and Vlieghe X. Thiation under microwave irradiation I: synthesis of phenothiazines. Sulfur Lett. 21 (1998) 191-198
20. Ippolito J.A., and Steitz T.A. A 1.3-Å resolution crystal structure of the HIV-1 trans-activation response region RNA stem reveals a metal ion-dependent bulge conformation. Proc. Natl. Acad. Sci. USA 95 (1998) 9819-9824
21. Bayer P., Kraft M., Ejchart A., Westendorp M., Frank R., and Rösch P. Structural studies of HIV-1 Tat protein. J. Mol. Biol. 247 (1995) 529-535
22. Murchie A.I.H., Davis B., Isel C., Afshar M., Drysdale M.J., Bower J., Potter A.J., Starkey I.D., Swarbrick T.M., Mirza S., et al. Structure-based drug design targeting an inactive RNA conformation: exploiting the flexibility of HIV-1 TAR RNA. J. Mol. Biol. 336 (2004) 625-638
23. Peng J.W., Lepre C.A., Fejzo J., Abdul-Manan N., and Moore J.M. Nuclear magnetic resonance-based approaches for lead generation in drug discovery. In: James T.L., Dötsch V., and Schmitz U. (Eds). Methods in Enzymology Volume 338 (2001), Academic Press, San Diego 202-230